Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04055571|
Recruitment Status : Recruiting
First Posted : August 13, 2019
Last Update Posted : August 13, 2019
|Condition or disease|
|Benign or Malignant Pancreatic Diseases|
It is reported in the literature that the treatment of any pancreatic disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The investigator's goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality, and morbidity.
The main aim of this study is to evaluate and compare the outcomes from the investigator's decisions on multiple treatments of benign or malignant pancreatic diseases.There is a need to understand and improve the current diagnosis and treatment algorithm for pancreatic pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery.
All past patients who were treated for a particular benign or malignant pancreatic disease process under evaluation from 2005 to present will be included in this study.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases|
|Actual Study Start Date :||March 5, 2019|
|Estimated Primary Completion Date :||January 30, 2025|
|Estimated Study Completion Date :||January 30, 2025|
- Overall survival [ Time Frame: 2005 to 2019 ]Number of patients who have been diagnosed with benign or malignant pancreatic disease
- Mortality [ Time Frame: 2005 to 2019 ]Number of patients who have been diagnosed with benign or malignant pancreatic disease
- Morbidity [ Time Frame: 2005 to 2019 ]Number of patients who have been diagnosed with benign or malignant pancreatic disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04055571
|Contact: Crystee Cooper, DHEd||214-947-1280||CrysteeCooper@mhd.com|
|Contact: Nitasha Phatak, Ph.D.||214-947-4459||NitashaPhatak@mhd.com|
|United States, Texas|
|Trinity Surgical Consultants, Methodist Richardson Medical Center||Recruiting|
|Richardson, Texas, United States, 75082|
|Contact: Dhiresh R Jeyarajah, MD 972-619-3500|
|Principal Investigator:||Dhiresh Jeyarajah, M.D.||Methodist Richardson Medical Center|